{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T02:05:23Z","timestamp":1781316323368,"version":"3.54.1"},"reference-count":20,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2019,3,8]],"date-time":"2019-03-08T00:00:00Z","timestamp":1552003200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The efficacy of ibrutinib has been demonstrated in patients with chronic lymphocytic leukemia (CLL), including as first\u2010line therapy. However, outcomes after ibrutinib discontinuation have previously been limited to higher\u2010risk populations with relapsed\/refractory (R\/R) disease. The objective of this study was to evaluate outcomes of ibrutinib\u2010treated patients based on prior lines of therapy, including after ibrutinib discontinuation. Data were analyzed from two multicenter phase 3 studies of single\u2010agent ibrutinib: RESONATE (PCYC\u20101112) in patients with R\/R CLL and RESONATE\u20102 (PCYC\u20101115) in patients with treatment\u2010naive (TN) CLL without del(17p). This integrated analysis included 271 ibrutinib\u2010treated non\u2010del(17p) patients with CLL (136 TN and 135 R\/R). Median progression\u2010free survival (PFS) was not reached for subgroups with 0 and 1\/2 prior therapies but was 40.6 months for patients with \u22653 therapies (median follow\u2010up: TN, 36\u2009months; R\/R, 44\u2009months). Median overall survival (OS) was not reached in any subgroup. Overall response rate (ORR) was 92% in TN and 92% in R\/R, with depth of response increasing over time. Adverse events (AEs) and ibrutinib discontinuation due to AEs were similar between patient groups. Most patients (64%) remain on treatment. OS following discontinuation was 9.3 months in R\/R patients (median follow\u2010up 18\u2009months, <jats:italic>n\u2009=<\/jats:italic> 51) and was not reached in TN patients (median follow\u2010up 10 months, <jats:italic>n\u2009=<\/jats:italic> 30). In this integrated analysis, ibrutinib was associated with favorable PFS and OS, and high ORR regardless of prior therapies in patients with CLL. The best outcomes following ibrutinib discontinuation were for patients receiving ibrutinib in earlier lines of therapy.<\/jats:p>","DOI":"10.1002\/ajh.25436","type":"journal-article","created":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T07:14:20Z","timestamp":1550214860000},"page":"554-562","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Outcomes with ibrutinib by line of therapy and post\u2010ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis"],"prefix":"10.1002","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2481-7504","authenticated-orcid":false,"given":"Susan M.","family":"O'Brien","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology University of California Irvine  Irvine California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Byrd","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology The Ohio State University Medical Center  Columbus Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hillmen","sequence":"additional","affiliation":[{"name":"Department of Haematology St James's University Hospital  Leeds United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Coutre","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology Stanford University School of Medicine  Stanford California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R.","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematological Malignancies Dana\u2010Farber Cancer Institute  Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Barr","sequence":"additional","affiliation":[{"name":"Department of Medicine Wilmot Cancer Institute, University of Rochester  Rochester New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline C.","family":"Barrientos","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology and Medical Oncology Hofstra Northwell School of Medicine  Hempstead New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Devereux","sequence":"additional","affiliation":[{"name":"Department of Life Sciences and Medicine, Division of Cancer Studies Kings College Hospital  London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3411-6357","authenticated-orcid":false,"given":"Tadeusz","family":"Robak","sequence":"additional","affiliation":[{"name":"Department of Hematology Medical University of Lodz and Copernicus Memorial Hospital  \u0141\u00f3d\u017a Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishitha M.","family":"Reddy","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology Vanderbilt University Medical Center  Nashville Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Kipps","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology\u2010Oncology UC San Diego Health, Moores Cancer Center  San Diego California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Tedeschi","sequence":"additional","affiliation":[{"name":"Department of Hematology Azienda Ospedaliera Niguarda C\u00e0 Granda  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Cymbalista","sequence":"additional","affiliation":[{"name":"Service Hematologie Biologique H\u00f4pital Avicenne, Universit\u00e9 Paris 13  Bobigny France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Ghia","sequence":"additional","affiliation":[{"name":"Strategic Research Program in CLL, Division of Experimental Oncology Universit\u00e8 Vita\u2010Salute San Raffaele and IRCCS Ospedale San Raffaele  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Chang","sequence":"additional","affiliation":[{"name":"Biostatistics Pharmacyclics LLC, an AbbVie Company  Sunnyvale California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joi","family":"Ninomoto","sequence":"additional","affiliation":[{"name":"Clinical Science Pharmacyclics LLC, an AbbVie Company  Sunnyvale California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danelle F.","family":"James","sequence":"additional","affiliation":[{"name":"Clinical Science Pharmacyclics LLC, an AbbVie Company  Sunnyvale California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan A.","family":"Burger","sequence":"additional","affiliation":[{"name":"Department of Leukemia, Division of Cancer Medicine University of Texas MD Anderson Cancer Center  Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,3,8]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-390989"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-328484"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-548610"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-386417"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-07-515361"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400376"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.3331.3331"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-603670"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2014.218"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-606038"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.233.233"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.182907"},{"key":"e_1_2_8_15_1","unstructured":"KippsTJ FraserC CoutreSE et al.Outcomes of ibrutinib\u2010treated patients with chronic lymphocytic leukemia\/small lymphocytic leukemia with high\u2010risk prognostic factors in an integrated analysis of 3 randomized phase 3 studies. In: XVII International Workshop on Chronic Lymphocytic Leukemia; 2017; New York New York."},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.4390.4390"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.719.719"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-716977"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.715.715"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.715.715"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.234.234"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.25436","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.25436","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.25436","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.25436","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T06:55:57Z","timestamp":1693896957000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.25436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,8]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["10.1002\/ajh.25436"],"URL":"https:\/\/doi.org\/10.1002\/ajh.25436","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,8]]},"assertion":[{"value":"2018-10-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}